In our study, we demonstrated that disruption of the P300/LINC00501 axis by C646 inhibits the tumour growth of GC without significant sign of side effect, indicating that the P300/LINC00501 axis as a therapeutic target in GC. This evidence concerns the gene EP300 and gastric cancer.